Sign in
CompletedNo phase

Ventricular Catheter Ablation Study (VCAS)

Key facts

Who runs it
Field Medical
Where
Czechia2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
34 people enrolled
Started
12 Apr 2024
Ended
28 Nov 2025
Type of study
Interventional, 2 groups
Treatments tested
  • FieldForce™ Ablation System Ventricular Tachycardia
  • FieldForce™ Ablation System Premature Ventricular Contractions
Record updated
14 May 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 28 criteriaShow less

Other criteria

  • INCLUSION:
  • Signed patient informed consent form (ICF)
  • Female and male participants between 18 and 80 years
  • For VCAS-I group, patients with VT meeting class II-a/b indications in European guideline for catheter ablation, with a clinical VT event detected by an implanted ICD
  • For VCAS-II group, patients with frequent premature ventricular complexes (PVCs) meeting class II-a/b indications based on European guidelines for catheter ablation
  • For VCAS-II, documentation of frequent PVCs by 24 hours Holter with >15% PVC burden for asymptomatic patients and >5% PVC burden for symptomatic patients within the last 60 days; EXCLUSION:
  • Body Mass Index > 40
  • Pacemaker dependence
  • Ineligible for ablation according to Physician judgement (including but not limited to known to have protruding left ventricular thrombus or have implanted mechanical aortic and mitral valves)
  • Recent MI (less than 90 days) or another reversible cause of VT (e.g., electrolyte abnormalities, drug-induced arrhythmia)
  • The presence of inferior vena cava embolic protection filter devices
  • Recent cardiac surgery (less than 2 months)
  • NYHA Class IV
  • Hemodynamically severe valvular disease that precludes ablation. Severity will be evaluated by using echocardiography, according to AHA and European guidelines
  • Uncontrolled abnormal bleeding and/or clotting disorder
  • Contraindication to systemic or oral anticoagulation
  • Serious or untreated medical conditions that would prevent participation in the study, interfere with assessment or therapy, or confound data or its interpretation, including but not limited to solid organ or hematologic transplant, or currently being evaluated for an organ transplant
  • Severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gases or significant dyspnea
  • Chronic renal insufficiency of eGFR< 30 mL/min/1.73 m2
  • Active malignancy
  • Untreated clinically significant infection
  • Life expectancy is less than one year
  • Clinically significant psychological condition that in the investigator's opinion would prohibit the subject's ability to meet the study requirements
  • Prohibitively distorted cardiac anatomy due to congenital heart disease
  • Had a recent percutaneous coronary intervention (<1 month)
  • Participation in another investigational study or treatment with any investigational drug within the previous 30 days that would interfere with this study
  • Patient is not able to understand the nature of this study or is unwilling or unable to attend the study procedures
  • Pregnancy or breastfeeding

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a prospective safety and feasibility study to evaluate the safety of the FieldForce™ Ablation system in patients with ventricular arrhythmia divided into two groups: VT (VCAS-I) and frequent premature ventricular complex (VCAS-II).

The 2 groups in the trial

  • Ventricular Tachycardia (VCAS-I)Treatment being tested

    Patients with ventricular tachycardia meeting class II-a/b indications in European guideline for catheter ablation, with a clinical VT event detected by an implanted ICD

    Treatment: FieldForce™ Ablation System Ventricular Tachycardia

  • Premature Ventricular Contractions (VCAS-II)Treatment being tested

    For VCAS-II group, patients with symptomatic frequent unifocal premature ventricular complexes (PVCs) meeting class II-a/b indications based on European guidelines for catheter ablation. For VCAS-II, documentation of frequent PVCs by 24 hours Holter with \>15% PVC burden for asymptomatic patients and \>5% PVC burden for symptomatic patients within the last 60 days.

    Treatment: FieldForce™ Ablation System Premature Ventricular Contractions

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pre-Market, First-In-Human, Pilot, Interventional, Clinical Investigation to Evaluate Safety and Feasibility of the FieldForce™ Ablation System in Symptomatic Patients With Ventricular Arrhythmia
Publications
Record updated
14 May 2026